Brochure | February 18, 2026

Curia R&D Pipeline Overview

Source: Curia
Female researcher analyzing scientific samples-GettyImages-2231025177

This pipeline outlines a sequence of late‑stage and emerging therapeutics projected to launch between 2024 and 2031, spanning immunology, neurology, psychiatry, rare disease, oncology, and inflammatory disorders. The portfolio leans heavily toward next‑generation mechanisms, improved safety profiles, and first‑in‑class or best‑in‑class innovations.

access the Brochure!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Pharmaceutical Online

Please tell us more about you so that we can customize our newsletters to your specific interests:

Curia